Most forms of dementia have a genetic component, but only a small fraction follow the straightforward inheritance patterns people usually mean when they ask whether something “runs in the family.” Genetic factors are estimated to play a role in at least 80 percent of Alzheimer’s disease cases, yet for the vast majority of people, dementia risk is shaped by a web of common gene variants interacting with lifestyle, health conditions, and aging itself. The distinction between a disease that is “genetic” and one that is “hereditary” matters here more than in almost any other condition, and understanding it can change how you think about your own risk.
The Difference Between Hereditary and Genetic
When researchers say dementia is “genetic,” they mean that DNA influences who develops it and who does not. When they say it is “hereditary,” they typically mean a specific mutation passed from parent to child can directly cause the disease. Almost all dementia is genetic in the broad sense. A much smaller slice is hereditary in the strict sense. Twin and family studies suggest that genes account for a large share of Alzheimer’s susceptibility, but fewer than five percent of all Alzheimer’s cases are caused by single-gene mutations that guarantee the disease will develop.
Researchers often describe dementia genetics along a continuum. At one end sit rare, high-penetrance mutations where inheriting the gene virtually ensures disease onset, usually before age 60. At the other end sit common genetic variants that nudge your risk up or down modestly and interact heavily with environmental factors. Most people’s risk falls toward that second end of the spectrum.
Early-Onset Familial Alzheimer’s Disease
The clearest example of truly hereditary dementia involves mutations in three genes: APP, PSEN1, and PSEN2. Mutations in these genes cause familial Alzheimer’s disease, and they produce early-onset symptoms, often appearing in a person’s 40s or 50s.1PubMed. An overview of the genes and biomarkers in Alzheimer’s disease These mutations follow autosomal dominant inheritance, meaning a child of someone carrying the mutation has a roughly 50 percent chance of inheriting it, and if they do, they will almost certainly develop the disease.
PSEN1 mutations are the most common cause of autosomal dominant Alzheimer’s, with hundreds of different variants identified across families worldwide.2Alzheimer’s & Dementia. Molecular and functional analysis using Presenilin‐1 G206A mutation iPSC lines to understand age‐of‐onset variability in autosomal dominant Alzheimer disease Even within this category, though, the picture is not perfectly simple. Different PSEN1 mutations can produce different ages of onset, meaning two families carrying different mutations in the same gene might see symptoms appear a decade apart. APP mutations are rarer, and PSEN2 mutations rarer still, but they follow the same inheritance logic.
These families account for a very small proportion of all Alzheimer’s cases. If you have a parent or sibling who developed Alzheimer’s after age 65, the odds that a single dominant mutation is responsible are low. The hereditary forms are disproportionately concentrated among people with very early symptom onset and a clear pattern of affected relatives across multiple generations.
APOE and Late-Onset Alzheimer’s Risk
For the more than 95 percent of Alzheimer’s cases that appear after age 60, genetics still matters enormously, but through a different mechanism. The APOE gene comes in three common versions: ε2, ε3, and ε4. Everyone carries two copies. The ε4 variant is the single strongest genetic risk factor for late-onset Alzheimer’s, found in roughly 40 to 65 percent of all Alzheimer’s patients.3PubMed Central. Apoe4 and Alzheimer’s Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies Carrying one copy of ε4 increases your risk; carrying two copies increases it substantially more.
A large analysis using UK Biobank, FinnGen, and neuropathologically confirmed cases estimated that the ε3 and ε4 alleles together account for roughly three-quarters of the Alzheimer’s burden in the populations studied. In the dataset using neuropathologically confirmed diagnoses, the combined contribution was even higher, with ε4 alone estimated to account for about 57 percent of confirmed Alzheimer’s burden.4npj Dementia. The proportion of Alzheimer’s disease attributable to apolipoprotein E Those are striking numbers, but they describe population-level risk attribution, not individual destiny. Plenty of people carry ε4 and never develop dementia, and plenty of people without ε4 do develop it.
The ε2 variant, by contrast, appears to be protective. People with two copies of ε2 have the lowest observed rates of Alzheimer’s. The common ε3 variant, which most people carry, was long considered neutral. But the same analysis found that ε3 itself contributes meaningfully to population-level Alzheimer’s risk when compared against ε2 as the baseline, suggesting the “default” version of the gene is not as benign as once assumed.4npj Dementia. The proportion of Alzheimer’s disease attributable to apolipoprotein E
Beyond APOE, dozens of other common gene variants each contribute a small nudge to Alzheimer’s risk. Researchers combine these into polygenic risk scores. A study using 21 known risk loci found that people with high polygenic scores had meaningfully elevated odds of developing the disease, and this genetic architecture was shared across both early-onset and late-onset forms of sporadic Alzheimer’s.5PubMed Central. Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms No single one of these small-effect variants is “the gene for Alzheimer’s” the way PSEN1 is for the familial form, but together they shape the landscape of who gets sick.
Genetics of Non-Alzheimer’s Dementias
Alzheimer’s accounts for the majority of dementia cases, but other types have their own genetic stories. Dementia with Lewy bodies shares genetic risk factors with both Alzheimer’s and Parkinson’s disease. The APOE ε4 allele raises risk for Lewy body dementia too, and variants in the GBA and SNCA genes are also implicated.6PubMed Central. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions A genome-wide study using UK Biobank data confirmed that the SNCA and APOE regions harbor loci specific to Lewy body dementia even after accounting for their overlap with Alzheimer’s and Parkinson’s genetics.7PubMed Central. Disease-predominant loci across Alzheimer’s disease, Parkinson’s disease and Lewy body dementia: evidence from the UK Biobank prospective cohort, conditional GWAS and colocalization GBA mutations, which cause a lipid-storage disorder called Gaucher disease in their more severe forms, also modify risk for Parkinson’s disease and Lewy body dementia at lower dosages.8Archives of Neurology. Glucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders
Vascular dementia, caused by impaired blood flow to the brain, generally has weaker direct genetic links than Alzheimer’s. However, a hereditary form exists: mutations in the NOTCH3 gene cause a condition called CADASIL, which leads to small-vessel disease in the brain and is a recognized cause of subcortical vascular dementia.9PubMed Central. The role of NOTCH3 variants in Alzheimer’s disease and subcortical vascular dementia in the Chinese population Outside of CADASIL, vascular dementia risk is driven more by cardiovascular health, diabetes, and blood pressure than by specific gene variants, though genetic predisposition to those conditions creates an indirect link.
Inherited prion diseases are perhaps the most dramatic example of hereditary dementia. Conditions like familial Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia are all caused by mutations in a single gene, PRNP.10PubMed. Genetic causes and modifiers of prion diseases These are extremely rare, but their inheritance is autosomal dominant: each child of a carrier has a 50 percent chance of inheriting the mutation. One recent study even found evidence that the rate of transmission of certain PRNP mutations to offspring may exceed the expected 50 percent, depending on which parent carries the variant.11PubMed Central. The Risk of Transmission of Genetic Prion Diseases is Greater Than 50
Lifestyle Can Offset Genetic Risk
One of the most practically important findings in dementia genetics is that your genes are not a fixed verdict. A large UK Biobank study found that among people with high genetic risk for dementia, those who followed a favorable lifestyle had a meaningfully lower chance of developing the disease compared to those with an unfavorable lifestyle. About 1.1 percent of high-genetic-risk participants with favorable lifestyles developed dementia, versus about 1.8 percent of high-genetic-risk participants with unfavorable lifestyles.12JAMA. Association of Lifestyle and Genetic Risk With Incidence of Dementia There was no significant interaction between the genetic risk score and lifestyle, meaning a healthy lifestyle was associated with lower dementia risk regardless of whether someone’s genetic profile put them in a high-risk or low-risk category.
A separate study looking specifically at cognitive decline over time found that people with favorable lifestyles experienced roughly a third slower rate of cognitive decline than those with unfavorable lifestyles, and this held true for both low and high genetic risk groups.13Nature Communications. Integrated healthy lifestyle even in late-life mitigates cognitive decline risk across varied genetic susceptibility The lifestyle factors consistently linked to lower risk include physical activity, not smoking, moderate alcohol intake, a healthy diet, and social engagement. None of these erase genetic risk entirely, but they appear to meaningfully blunt it.
Epigenetics as a Bridge Between Genes and Environment
How does a lifetime of exercise or a poor diet end up affecting a process rooted in your DNA? Epigenetics is one candidate mechanism. Your genes do not change over your lifetime, but the chemical tags that control whether genes are turned on or off do. These include modifications like DNA methylation and histone changes, and they can be influenced by nutrition, stress, physical activity, and environmental toxins.14PubMed Central. Epigenetics as a link between environmental factors and dementia risk
In Alzheimer’s specifically, epigenetic changes associated with the disease include abnormal DNA methylation patterns and histone modifications that alter gene expression in the brain.15PubMed Central. Alzheimer’s Disorder: Epigenetic Connection and Associated Risk Factors More recently, researchers have shown that blood-based epigenetic markers of chronic inflammation predict brain shrinkage, cognitive decline, and long-term dementia risk.16PubMed Central. DNA Methylation Signatures of Systemic Inflammation Are Associated With Brain Volume, Cognitive Trajectories, and Long-Term Dementia Risk This work is still relatively young, but it offers a plausible biological explanation for why two people with the same APOE genotype can have very different outcomes depending on how they lived.
Does Ancestry Change the Genetic Picture?
The APOE ε4 allele is more common in people of African descent than in people of European descent. But paradoxically, the increase in dementia risk associated with carrying ε4 appears to be smaller in Black individuals than in White individuals.17PubMed Central. The Relationship of APOE ε4, Race, and Sex on the Age of Onset and Risk of Dementia This does not mean the gene is harmless in Black populations, just that other genetic or environmental factors appear to modify its effect differently. Data from the All of Us research program found that Hispanic/Latino and Black participants had a higher baseline risk of dementia overall, and that APOE4 carriers in all three groups (Hispanic/Latino, Black, and White) had comparably increased hazard ratios compared to non-carriers within their own group.18PubMed Central. Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program
An analysis pooling seven population-based cohort studies found that the detrimental effect of ε4/ε4 compared with ε3/ε3 was present in both Black and White participants.19PubMed Central. The Association Between APOE Genotype, Race, and Dementia: An Analysis of 7 Population-Based Cohort Studies The debate centers on degree, not direction. One mechanism that may contribute to ancestry-related differences involves chromatin accessibility: in one study, APOE ε4 was expressed at higher levels in brain cells from individuals of European ancestry compared to African ancestry, which could partly explain the stronger risk association seen in European-descent populations.20PubMed Central. Ancestry-related differences in chromatin accessibility and gene expression of APOE ε4 are associated with Alzheimer’s disease risk
Most large-scale dementia genetics studies have been conducted in populations of European descent, which means risk estimates, polygenic scores, and even the list of known risk genes are biased toward that group. For people of other backgrounds, the published risk numbers may not translate directly, and genetic counseling based on those numbers should come with that caveat.
What Genetic Testing Can and Cannot Tell You
If you have a strong family history of early-onset dementia across multiple generations, genetic testing for APP, PSEN1, and PSEN2 mutations can provide a definitive answer about whether a hereditary form is present. For frontotemporal dementia, testing for mutations in genes like MAPT, GRN, and C9ORF72 follows a similar logic. Professional guidelines generally recommend that testing start with an affected family member when possible, to confirm whether a genetic cause exists in the family before offering predictive testing to healthy relatives.21Alzheimer’s & Dementia. Developing a consensus protocol for genetic testing in frontotemporal dementia
For late-onset Alzheimer’s, APOE testing is available but more complicated to interpret. Carrying one or two copies of ε4 raises your risk, but it does not mean you will develop the disease, and lacking ε4 does not mean you won’t. Learning your APOE status can prompt useful health decisions for some people, but it can also cause anxiety without clear actionability. Research on the psychological effects of predictive genetic testing for hereditary dementias has found that structured counseling protocols generally lead to no lasting psychological harm and can even help with future planning.22PubMed Central. Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia The IT-DIAfN Protocol However, testing without adequate support, especially when results are ambiguous, can generate significant distress.23PubMed. The psychological impact of genetic testing for Alzheimer disease
A study of dementia patients who underwent detailed genetic evaluation found that a positive family history was reported in 42 percent of Alzheimer’s cases and 48 percent of frontotemporal dementia cases. Among those flagged as high-risk based on family history and clinical features, 38 percent turned out to carry a variant considered diagnostically significant.24PubMed. Assessing family history and approaches for identifying patients with dementia with diagnostically significant genetic findings That means family history is a useful but imperfect signal. Many people with affected relatives carry no identifiable high-risk variant, and some people with no family history carry one.
Somatic Mutations and Sporadic Cases
One emerging area of research addresses a puzzling question: if most dementia cases are “sporadic” (not inherited), where does the genetic component come from? Part of the answer may involve somatic mutations, which are DNA changes that arise in individual cells during a person’s lifetime rather than being inherited from a parent. A deep sequencing study of brain and spinal cord tissue from nearly 400 sporadic cases of ALS and frontotemporal dementia found potentially harmful somatic variants in known disease genes in about two percent of cases that lacked inherited mutations. These variants occurred at very low levels, sometimes present in fewer than two percent of cells, and were often concentrated in disease-affected brain regions.25PubMed Central. Somatic mosaicism in ALS and FTD identifies focal mutations associated with widespread degeneration The finding suggests that in a small subset of people with no family history, a mutation that arose after conception, rather than being passed down, may still be driving disease.
Why APOE ε4 Still Exists
If ε4 is so bad for the aging brain, why hasn’t evolution gotten rid of it? The question has attracted genuine interest from anthropologists and neuroscientists. One hypothesis is that ε4 was actually the ancestral version of the gene carried by all early humans, and that physical activity levels common among hunter-gatherers may have counteracted its harmful effects on the brain and cardiovascular system. According to this idea, the evolution of endurance-based physical activity about two million years ago reduced the amyloid and vascular burden associated with ε4, allowing humans to live longer despite carrying a genotype that, in a sedentary modern context, promotes disease.26PubMed Central. Exercise, APOE genotype, and the evolution of the human lifespan
A complementary hypothesis proposes that ε4 persisted because it conferred immune advantages. In environments with heavy pathogen exposure, particularly enteric infections, ε4 carriers may have had a survival edge earlier in life.27PubMed. Evolutionary Selection of APOEɛ4 Encourages Increased Focus on Immunity in Alzheimer’s Disease This type of trade-off, where a gene variant helps in youth but harms in old age, is a well-recognized pattern in evolutionary biology. The practical implication circles back to something the lifestyle data already suggest: the ε4 allele may be less dangerous in a body that moves and eats the way our ancestors did than in one living a modern sedentary life.
Gene-Targeted Therapies on the Horizon
Understanding the genetics of dementia is not just academic. It is opening the door to treatments designed around specific genetic targets. Antisense oligonucleotides, or ASOs, are short synthetic molecules that can bind to specific RNA sequences and dial down the production of disease-related proteins. In Alzheimer’s research, ASOs are being developed to target genes involved in amyloid production and other pathological pathways.28PubMed Central. Antisense oligonucleotides for Alzheimer’s disease therapy: from the mRNA to miRNA paradigm Recent work has even demonstrated proof-of-concept ASOs that can silence more than one Alzheimer’s-related gene simultaneously, achieving reductions in amyloid production of up to 70 percent in cell models.29Molecular Therapy Nucleic Acids. Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer’s disease
These approaches are still early-stage, but they represent a shift in thinking. Rather than treating dementia as a single disease with one drug target, gene-based strategies could eventually allow treatments tailored to the specific genetic variant driving a person’s disease. For carriers of rare dominant mutations like PSEN1, who face near-certain disease, such therapies could be transformative. Brain imaging research in presymptomatic carriers of autosomal dominant Alzheimer’s mutations has already shown detectable structural changes years before symptom onset, which could help identify the right window for intervention.30PubMed Central. Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort The genetics of dementia, in other words, is not just telling us who is at risk. It is increasingly pointing toward what to do about it.